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METHOTREXATE FOR THE TREATMENT OF PATIENTS WITH 
MULTIPLE EPISODES OF ACUTE CARDIAC AmGRAFT 
REJECTION. JD Hosenut& FE Hershberger, DJ 
Norman, H Hovaguimian, A Cobanoglu. The Oregon 
Cardiac Transpiant Program, Portland, Oregon. 
Of 125 cardiac allograft recipients 
transplanted from December 1985 to August 1990, 
3 females and 6 males with a mean age of 43+11 
yrs required multiple (10.3f3.6) courses of 
antirejection treatment over a total follow-up 
period of 29&14 months. The underlying cardiac 
disease was cardiomyopathy in 8 of the 9 
patients. These patients were selected to 
receive Methotrexate (10 mg/wk for 6 wks). 
Rejection treatment prior to Methotrexate 
included 6 courses of OKT3, 22 courses of high 
dose steroids and 45 courses of low dose 
steroids for the entire group. The average 
number of rejection treatments/patient prior to 
Methotrexate was 9.2f3.9 treatments or 
0.7320.27 treatments/m0 follow-up. Following 
Methotrexate the average number of rejection 
treatments fell to 1.251.1 treatments or 
O.lO&O.ll treatments/m0 follow-up (PcO.0001). 
Six pts responded to a single course of 
Hethotrexate, 2 pts required two courses 
(second course 20 mg/wk for 6 wks) and a single 
patient reguired 3 courses of Methotrexate 
therapy. The only complication associated with 
Methotrexate therapy was 1 pt who developed CMV 
interstitial pneumonitis while on therapy. 
Methotrexate appears extremely effective in 
halting repeated episodes of rejection in the 
subset of patients who have had multiple 
episodes of acute rejection. 
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CHRONIC AMIODARONE THERAPY PRIOR TO CARDIAC 
TRANSPLANTATION DOES NOT INCREASE THE PERI- 
Stevenson, 
Jon Kobashigawa, William G. 
Holly Middlekauff: Erica Brownfield, Jaime Moriguchi, 
Michele Hamilton, Davis Drinkwater, Hillel L&s, Lynne W. 
Stevenson. UCLA Medical Center, LOS Angeles, CA 
Although pts awaiting cardiac transplant (CI’x) often have life- 
threatening arrhythmias for which amiodarone (AMIO) may be 
beneficial, AMIO use in this popuIation has been limited by 
concern that it would compromise post-CTx course, particularly 
with pulmonary complications. To test this hypothesis, we 
compared the early post-CTx course of 28 pts on AM10 
(400&250mg, for 9~22 mos) prior to CTx with that of 28 age 
matched CI’x pts without AMIO. No AM10 pt received OKT3 for 
induction of immunosuppression. The AM10 pts had no increase in 
time intubated or chrono/inotropic support (C/I). 
Hours intubated %% 
Control P 
Discharge Oa sat % 96:l 
26225 p=ns 
Hours paced 
97~2 
16~26.4 
p<o.os 
Days on C/I 
2.4~7.2 p=o.o6 
Discharge heart rate 
2.2~1.6 3.3~1.2 
77~8.4 
pco.05 
Inpatient days 
86&12 
9.2~2.7 
p<o.os 
14k9 p<o.os 
AMIOpts were discharged after mean 9 days, with normal oxygen 
saturatton and slightly lower heart rate than controls. The 30-day 
mortality was 7% (2 pts) comparable to the 5% in the UCLA 
experience @=ns). 
There is no evidence that chronic amiodarone therapy 
compromises pulmonary function or general course after Ctx in pts 
receiving standard triple drug immunotherapy. 
CALCIUM CHANNEL AN?AGONiS~ PROTECT AG 
DEVELOPMENT OF CORONARY ARTERY DIS 
CARDIAC TRANSPLANT 
jiefen Sheehan, George Vetrovec, Susan Graham, Pramod Mohanty and John 
McB Hodgson. McGulre VAMC ati Medical College of Virginia, Richmond, 
Virginia. 
Recent reports suggest that calcium channel antagonists (CCA) protect 
against development of new lesions In pts with mild to moderate coronary 
artery disease (CAD). Since CAD often develops in an accelerated fashlon 
following cardiac transplantation (CT), we hypothesized that the use of CCA 
may retard the early occurrence of CAD In pts after CT. We retrospectively 
reviewed 108 anglograms from pts studied foflowlng CT. Forty-seven % of pts 
were recefving CCA 01 these, 52% had no angiographfc evidence of CAD 
when studied at a mean of 24t2 mo after CT. In contrast, only 27% of 01s not 
recefving CCA were free of 
No CAD 52% 27% co.05 
Dfffuse Concentric Nanawing 34% 67% co.05 
Discrete/Multiple Stenosis 6% 5% ns 
Lumlnel Irregularities 6% 2% ns 
Proximal LAD D&meter (mm) 4.2tO.l 3.9tO.l co.05 
lime from Cl to Study (mo) 24~1.8 23t2.2 r&3 
Pts with CAD prior to CT 64% 55% ns 
Potentially confounding variables were analyzed. No differences were noted 
&w&en the two groups when comparing mean arterial pressure (112t2 vs 
116t2 mmHg), coronary frow reserve (2.6kO.l vs 2.4+0.1), left vertricular 
mass index (128e6 vs 132t7 am/m*) or chdesterol levels (244+10 vs 
243t9.3 mg/dl). These data suggest the use of CCA following CT exerts a 
protective effect against development of CAD. This phenomenon is most 
effective In slowing the development of diffuse rather than focai disease. 
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NORMALIZATION OF HEART RATE RESPONSE AND EXERCISE DURA- 
TION WITH LIMITED IMPROVEMENT IN MAXIMAL OXYGEN CONSUMP- 
TION IN LONG-TERM CARDIAC TRANSPLANT RECIPIENTS. 
Rebecca J. Quisq Jeanne Salyer. Andrew Glatt. Ketan 
Kapadia, Albert huerraty and P.K. Mohantv. Med. Coll. of 
VA., Richmond, VA. 
Previous studies have demonstrated reduced exercise capa- 
city in patients following orthotopic cardiac transplan- 
tation (TX). This is predominantly due to blunted and 
delayed heart rate (HR) response. To determine whether 
HR response and exercise cabacity can improve over time, 
24 pts (l.Omo to 4.lyrs post TX) were studied by maximal 
treadmill exercise (RQ>l) on the Bruce protocol with mea- 
surement of maximal O2 consumption (VO max). To evaluate 
exercise parameters over time, ots wer g divided into 3 
groups: Grl, <lyr (n=7): Gr2, 112yrs (n-5): Gr3, >2yrs 
(n=12). There were no differences in donor heart age, 
ischemic time, or LV ejection fraction among the groups. 
Data are expressed as mean+SEM. *p<O.O5 vs Grl: +p<D.O5 
vs Gr2. 
Recipient age (yrs) 
Exercise duration (min) 5:3TlO 
Group 2 C$J;W~~ 
43. S+8 
V02max (ml/kg/min) 
6.871.0 i.370 9*+ 
HR max (bpm) 
16.472.0 18.5T1.6 21:5?1:1" 
12779 13873 15576*+ 
These results indicate that Leak exercTse HR and-exercise 
duration return toward normal in the long term after TX. 
Although, VO max 
ill remains 8 
improves significantly over time, it st- 
epressed. Improvement in HR resoonse may 
account for increased exercise duration, with-only limit- 
ed improvement in VO,max. Lack of normalization of MVO, 
may be due to decreafed absolute change in HR and/or ab5 
normal peripheral 0 
Normalized HR 
uptake which persist despite TX. 
respo ii se may be the result of enhanced cir- 
culating catecholamine response to exercise and/or card- 
iac reinnervation in long-term TX recipients. 
